CME czar brings considerable skills, reputation to Pfizer

Pfizer, in the midst of revamping its CME department, scored a coup with the recent hiring of Maureen Doyle-Scharff, MBA, as director, medical education, US external medical affairs.

Doyle-Scharff comes from the Ross Products division of Abbott Labs, where for the last two years she directed healthcare education, policy and programs. She will remain in Ohio, where Ross is headquartered, while her new position is based in New York City.

A well-known advocate of CME among all provider groups, Doyle-Scharff holds positions on the boards of medical education advocacy groups. Before joining Ross, she was executive director, professional and strategic customer alliances for Johnson & Johnson.

Pfizer's Medical Education Grants department, under the direction of Mike Saxton, MEd, senior director, team leader, is placing more emphasis on the competency of personnel.

Earlier this year, the firm made reviewers in the department re-interview for jobs, with candidates required to meet higher standards.

Bringing in someone of high stature—who shares his vision—could put Saxton in a better position to implement his plans, say people familiar with the matter.

“Pfizer and others continue to strengthen their team,” said Tony Iacono, president, Access Medical Network. “The increased competencies will raise the bar throughout the CE community, better serving healthcare providers.”

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.